

NEWS RELEASE

Paris and Toulouse, France – March 24th, 2015

Eligibility of Genticel shares for PEA-PME

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today confirms that its shares are still eligible for the Equity Savings Plan, PEA-PME.

Genticel indeed still meets the PEA-PME eligibility criteria, which are specified in article D.221-113-5 of application decree n° 2014-283, dated March 4th, 2014:

- A total workforce of fewer than 5,000 employees;
- An annual turnover below €1.5 billion or total assets of less than €2 billion.

Therefore, Genticel shares can be included in PEA-PME accounts.

Financial calendar 2015

Each publication will be released after Euronext market closing.

28 April 2015	Update on 2015 1 st Quarter Business & Cash Position
11 June 2015	Annual Shareholders Meeting
28 July 2015	Update on 2015 2 nd Quarter Business & Cash Position
21 September 2015	2015 Half-Year Results
28 October 2015	Update on 2015 3 rd Quarter Business & Cash Position

Upcoming Genticel meetings with investors

25 April 2015	VFB Investor Happening - Brussels, Belgium
27 & 28 April 2015	Small & Midcap Event - Paris

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

In 2015, Genticel licensed its Vaxiclase technology to Serum Institute of India Ltd. (SII), the largest vaccine producer in the world, for use as a component in acellular multivalent combination vaccines including pertussis antigens.

Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit Genticel's website, www.genticel.com



GENTICEL CONTACT
Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

USA INVESTOR CONTACT
Brian Stollar
Tel.: +1 (212) 915 2577
bstollar@lifesciadvisors.com

INVESTOR CONTACT
Corinne Puissant
Tel.: +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS CONTACT
Alexandra Prisa
Tel.: +33 (0)1 53 67 36 90
aprisa@actus.fr